Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > RealityCheck4U here - after 3+ years as TH holder

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Apr 17, 2021 5:59pm

107 Views

Post# 33017872

RE:RE:RE:RE:RE:RE:RealityCheck4U here - after 3+ years as TH holder

Did you read my post put up a few times on the value of the oncology option using market comps? Each cancer indication could see peak revenues of between $1-$2bil at just the 4L level. TNBC would be largest. Put a 7x multiple on that. Quite easy to get there is they have success with just oncology. If you add in NASH in 5 years, even bigger.